Dr. Madiha Naseem, MD

Dr. Naseem practices at Adventist Health Bakersfield in Bakersfield, California, part of Adventist Health.

Dr. Naseem's NPI, 1245734912, was assigned on March 19, 2018. Dr. Naseem graduated from University of Toronto Faculty of Medicine in 2016. Dr. Naseem's California license number on file is A166982.

Dr. Naseem's primary practice is Adventist Health Bakersfield, at 2615 Chester Avenue, Bakersfield, CA 93301 in Kern County. The practice phone is (661) 395-3000.

Dr. Naseem's primary practice is Adventist Health Bakersfield in Bakersfield, California, part of Adventist Health. Dr. Naseem is also affiliated with Adventist Health Delano. The medical group on file is Adventist Health Bakersfield. Dmand AI also links Dr. Naseem to 2 more medical groups and 1 group practice or clinic, each named with a free account. Dr. Naseem's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Naseem practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Naseem's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Naseem is board certified in internal medicine by the American Board of Internal Medicine. Dr. Naseem has a license on file in California.

CMS data shows 50 Medicare services from Dr. Naseem across 3 procedure codes in 2024, for 42 Medicare patients. Medicare paid $6,150 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 42 Medicare patients who saw Dr. Naseem in 2024. The largest group is 65 to 74, with 21 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 48% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Naseem's median patient age at 64, with 66% women.

In 2024, Dr. Naseem wrote 753 Medicare Part D claims for 161 patients. 68% of them were for generic drugs. CMS names the drug for 492 of them, across 24 drugs with 11 or more claims each, at $1,269,169 in total drug cost. In 2023, CMS named 88 claims across 6 drugs.

Dr. Naseem accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Naseem as offering telehealth.

Dmand AI links 22 papers to Dr. Naseem, published from 2015 to 2022. 2018 was the busiest year, with 8. The most frequent topics are Colorectal Neoplasms, Biomarkers, Tumor and Fluorouracil. Dr. Naseem has published most often in Eur J Cancer. Dr. Naseem's most frequent co-authors are Heinz-Josef Lenz, MD, Wolfgang Michael Korn, MD and Joshua A. Millstein, DO.

CMS Open Payments shows 58 general payments to Dr. Naseem from 27 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $129.

Dr. Naseem graduated from University of Toronto Faculty of Medicine in 2016.

Dr. Naseem is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.